Merck & Co. Inc.
MRK | NYSE
$149.52
+$3.19 (+2.18%)
At close: Oct 30, 2026, 4:02 PM ET
$149.26
-$0.26 (-0.17%)
Pre-market:
Nov 2, 2026, 3:53 AM ET
Company Profile
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Robert Davis | Chairman, President & Chief Executive Officer |
| Caroline Litchfield | Executive Vice President & Chief Financial Officer |
| Betty D. Larson | Executive Vice President & Chief Human Resources Officer |
| Chirfi Guindo | Executive Vice President of Strategic Access, Policy & Communications |
| Dalton E. Smart | Senior Vice President of Finance, Principal Accounting Officer & Global Controller |
| David Michael Williams | Executive Vice President and Chief Information & Digital Officer |
| Dean Y. Li | Executive Vice President & President of Merck Research Laboratories |
| Gaurav K. Gupta | Executive Vice President and Chief Information & Digital Officer |
| Jennifer L. Zachary | Executive Vice President & General Counsel |
| Johannes J. Oosthuizen | Executive VP and President of Oncology & MSD International |
| Peter Dannenbaum | Vice President of Investor Relations |
| Richard R. DeLuca Jr. | Executive Vice President & President of Merck Animal Health |
Merck & Co. Inc.
| Country | United States |
| IPO Date | Jan 13, 1978 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 74,000 |
| CEO | Robert Davis |
Contact Details
126 East Lincoln Avenue Rahway,
New Jersey 07065 United States
Stock Details
| Ticker Symbol | MRK |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000310158 |
| CUSIP Number | 58933Y105 |
| ISIN Number | US58933Y1055 |
| SIC Code | 2834 |
Recent News
- 2 days ago / fool.comWhy Merck Stock Flew Higher on Friday
- 2 days ago / benzinga.comMerck One of Top Large-Cap Biopharma Picks-Analyst
- 2 days ago / zacks.comMerck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook
- 3 days ago / marketbeat.comMerck & Co., Inc. Q3 Earnings Call Highlights
- 3 days ago / fool.comMerck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction
- 3 days ago / seekingalpha.comMerck & Co., Inc. (MRK) Q3 2026 Earnings Call Transcript
- 3 days ago / zacks.comMRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up
- 3 days ago / 247wallst.comMerck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher
- 3 days ago / seekingalpha.comMerck: A Strong Quarter, But It's Time To Take A Step Back
- 3 days ago / zacks.comMerck (MRK) Surpasses Q3 Earnings and Revenue Estimates
Add to Watchlist
Select watchlists to add or remove MRK